Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors
Conditions
Interventions
VVD-130850
Pembrolizumab
Locations
20
United States
California Research Institute
Los Angeles, California, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
NEXT Austin
Austin, Texas, United States
MDACC
Houston, Texas, United States
NEXT Dallas
Irving, Texas, United States
Start Date
January 5, 2024
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
October 16, 2025
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Vividion Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions